Clinical Trials on Osteolysis, Essential

Total 934 results

Geron Corporation

Completed

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV)

Polycythemia Vera | Essential Thrombocythemia

United States, Germany, Switzerland
Copenhagen University Hospital at Herlev

Unknown

A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

Polycythemia Vera | Essential Thrombocythemia

Sweden, United Kingdom, Denmark, Netherlands
Aarhus University Hospital
University of Aarhus

Completed

Intensive Vasodilator Therapy in Patients With Essential Hypertension (Vasomore)

Essential Hypertension | High Blood Pressure

Denmark
University Health Network, Toronto
Novartis Pharmaceuticals

Completed

Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms

Myelofibrosis (MF) | Myeloproliferative Neoplasms (MPN) | Polycythemia Vera (PV) | Essential Thrombocythemia (ET)

Canada
Incyte Corporation

Recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

Myelofibrosis | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Relapsed or Refractory Primary Myelofibrosis | Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) | ET...

United States, Spain, Japan, Italy, Finland, United Kingdom, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Finland, Norway, Sweden, France, Germany, Italy, Turkey, Argentina, Chile, Ecuador, Spain, Switzerland
Regional Hospital Holstebro

Completed

Heart Rate Variability in White Coat Hypertension and Essential Hypertension

Healthy | White Coat Hypertension | Essential Hypertension

Denmark
Jiangxi University of Traditional Chinese Medicine
Nangang community healthcare center (Nanchang city, Jiangxi province, China) and other collaborators

Active, not recruiting

Heat-sensitive Moxibustion Self-administration in Patients in the Community With Primary Hypertension: Protocol for a Multi-center, Pragmatic, Non-randomized Trial

Primary Hypertension

China
Massachusetts General Hospital
Incyte Corporation

Recruiting

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Polycythemia Vera | Essential Thrombocythemia

United States
University Hospital, Angers

Recruiting

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. (BioScoreSMP)

Essential Thrombocythemia | Myeloproliferative Disorder | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
John Mascarenhas
Roche Pharma AG; The Leukemia and Lymphoma Society

Completed

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States
University Hospital, Brest

Completed

Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients (OUEST)

Polycythemia Vera | Essential Thrombocythemia

France
Cephalon

Completed

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Polycythemia Vera | Essential Thrombocytosis

United States
Inge Marie Svane

Completed

Dual Vaccine Trial in Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia

Denmark
Yi Yang

Recruiting

Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension

Essential Hypertension

China
University of Minnesota

Recruiting

Algorithms for Programming DBS Systems for ET

Essential Tremor

United States
Myles Mc Laughlin

Completed

Interphase Gap in Biphasic Stimulation in DBS for ET

Essential Tremor

Belgium
Ahn-Gook Pharmaceuticals Co.,Ltd
Korea University Guro Hospital; Dt&Sanomedics

Unknown

Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Radboud University Medical Center

Completed

Nijmegen Antihypertensive Management Improvement Study (NAMIS)

Primary Hypertension

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Primary Myelofibrosis | Splenomegaly | Hepatomegaly | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Polycythemia Vera | Essential Thrombocythemia

United States
Dr Yan Beauverd

Completed

Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure (MPNClot)

Polycythemia Vera | Thrombocythemia, Essential

Switzerland, United Kingdom
Sierra Oncology, Inc.

Terminated

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States, France, Germany, Canada, Australia
Icahn School of Medicine at Mount Sinai
The Leukemia and Lymphoma Society

Completed

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

Polycythemia Vera | Essential Thrombocythemia

United States
Jiangxi University of Traditional Chinese Medicine

Active, not recruiting

A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community

Primary Hypertension

China
Shenzhen Ausa Pharmed Co.,Ltd
Anhui Medical University

Completed

China Stroke Primary Prevention Trial (CSPPT)

Primary Hypertension

China
University of Cambridge
British Heart Foundation

Unknown

Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension (Pathway 1)

Essential Hypertension | Hypertension, Resistant to Conventional Therapy

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Primary Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Shenzhen People's Hospital

Recruiting

Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI

Essential Hypertension

China
Chinese Academy of Medical Sciences, Fuwai Hospital

Active, not recruiting

Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP)

Primary Hypertension

China
University Hospital, Brest

Recruiting

Myeloproliferative Neoplastic Diseases Observatory From Brest (OBENE)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

France
Incyte Corporation

Completed

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Polycythemia Vera | Thrombocytosis | Myelofibrosis

United States
Ottawa Hospital Research Institute
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR)... and other collaborators

Completed

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (AIRPORT-MPN)

Primary Myelofibrosis | Venous Thromboembolism (VTE) | Polycythemia Vera (PV) | Essential Thrombocythemia (ET) | JAK2 Mutation | Myeloproliferative Neoplasm (MPN)

Canada
Lynk Pharmaceuticals Co., Ltd

Withdrawn

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Queen's University, Belfast
Mayo Clinic; University Hospital Southampton NHS Foundation Trust; University... and other collaborators

Completed

Myeloproliferative Neoplasms: an In-depth Case-control Study (MOSAICC)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United Kingdom
InSightec
Health Canada

Not yet recruiting

Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001)

Essential Tremor | Neurology
Samil Pharmaceutical Co., Ltd.

Completed

To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers

Essential Hypertension | Diseases of the Circulatory System

Korea, Republic of
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
NYU Langone Health

Completed

Mapping the Target for the MRgFUS Treatment of Tremor

Parkinson's Disease | Tremor, Essential

United States
University Hospital, Bordeaux

Completed

Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms (PhiNESS)

Polycythemia Vera | Essential Thrombocythemia

France
Sanofi

Completed

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Hematopoietic Neoplasm

United States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
China Academy of Chinese Medical Sciences
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Completed

Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study

Hypertension, Resistant to Conventional Therapy | Primary Hypertension

China
Boryung Pharmaceutical Co., Ltd
Yonsei University; Kyungpook National University Hospital

Completed

A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers

Essential Hypertension | Hepatic Impairment

Korea, Republic of
Syntara
Parexel

Recruiting

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Myelofibrosis

Taiwan, Australia, Korea, Republic of, United States
Gilead Sciences

Completed

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Myelofibrosis

United States
University of Utah
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
S*BIO

Completed

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States, Australia
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Familial Myeloproliferative Disorders

Polycythemia Vera | Essential Thrombocythemia | Idiopathic Myelofibrosis

United States, Italy
Novartis Pharmaceuticals

Completed

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Primary Myelofibrosis (MF)

Japan

Clinical Trials on Osteolysis, Essential

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations